Multiple myeloma patient study shows promise for natural killer cellsDecember 08, 2015
A first-in-human Phase I study of multiple myeloma patients combined expanded cord blood-derived natural killer cells with transplantation of a patient's own stem cells and high-dose chemotherapy with little or none of the side effects seen with current treatments.
Multiple myeloma is a cancer that forms from white blood cells that are found in the bone marrow and are normally vital to a healthy immune system. Natural killer (NK) cells are white blood cells that roam through the blood stream, attacking infections and potentially cancer-causing cells. The technology to grow NK cells from umbilical cord blood was developed by Nina Shah, M.D., assistant professor and Elizabeth J. Shpall, M.D., professor in the department of Stem Cell Transplantation and Cellular Therapy at The University of Texas MD Anderson Cancer Center.
Results from the clinical study, led by Shah and Shpall, were presented today at the 57th Annual Meeting of the American Society of Hematology (ASH) annual conference in Orlando, Fla.
"Multiple myeloma is an incurable disease thought to be characterized by immune dysregulation and exhaustion, whereby proliferation of malignant plasma cells is not checked by the immune system," said Shah. "Long-term remissions in some patients after stem cell transplants from donors have been observed, but treatment-related toxicity limits the widespread use of this therapy."
Shah and Shpall's team enrolled symptomatic patients who qualified as candidates for high-dose chemotherapy drugs like melphalan, and transplantation of the patient's own stem cells.
"Successful natural killer cell expansion to target dose was achieved in all the patients," said Shah. "The cell therapy infusion resulted in no toxicity and no occurrences of graft-versus-host disease."
Graft-versus-host disease is a condition in which the patient's immune system is attacked by the donor stem cells. The disease can occur in patients who have received donor stem cells or immune.
Twelve patients were enrolled in the study and were divided into four separate groups, with each receiving different dose levels of cord blood-derived natural killer cells. Ten of the 12 patients demonstrated high-risk disease or relapse in disease prior to study participation.
MD Anderson team participants included Jessica McCarty, Eric Yvon, Ph.D., Hila Shaim, M.D., Muharrem Muftuoglu, Enli Liu, Catherine Sobieski, Simrit Parmar, M.D., Chitra Hosing, M.D., Sairah Ahmen, M.D., Yago Nieto, M.D., Ph.D., Qaiser Bashir, M.D., Krina Patel, Ian McNiece, Ph.D., Muzaffar Qazilbash, M.D. and Richard Champlin, M.D., all of the Department of Stem Cell Transplantation and Cellular Therapy; Li Li, Department of Experimental Radiation Oncology; Indreshpal Kaur, Department of Cancer Medicine; Robert Orlowski, M.D., Ph.D., Department of Lymphoma/Myeloma; Laurence Cooper, M.D, formerly of the Department of Pediatrics; Kai Cao, M.D., Department of Laboratory Medicine; and Dean Lee, M.D., Ph.D., Department of Pediatrics.
The study was funded by Celgene, Summit, N.J. and the High-Risk Multiple Myeloma Moon Shot program at MD Anderson.
University of Texas M. D. Anderson Cancer Center
Related Multiple Myeloma Current Events and Multiple Myeloma News Articles
Carnegie Mellon develops bio-mimicry method for preparing and labeling stem cells
Researchers led by Carnegie Mellon University Professor of Biological Sciences Chien Ho have developed a new method for preparing mesenchymal stem cells (MSCs) that not only leads to the production of more native stem cells, but also labels them with a FDA approved iron-oxide nanoparticle (Ferumoxytol).
Demand for radiotherapy will rise substantially over next 10 years
The demand for radiotherapy across all European countries will increase by an average of 16% between 2012 and 2025, with the highest expected increase being for prostate cancer cases (24%), according to a new study published in Radiotherapy and Oncology.
Preliminary study: Antibody therapy reduces cancer stem cells in multiple myeloma
An experimental antibody treatment decreased by half the number of cancer stem cells that drive the growth of tumors in nearly all patients with multiple myeloma, a cancer of the bone marrow and bone tissue, according to results of a preliminary clinical trial led by Johns Hopkins Kimmel Cancer Center scientists.
Combination therapy may be better than radiotherapy alone to treat aggressive brain cancer
Radiotherapy effectively damages brain tumors but the cancer cells can repair themselves in order to live on. Now, researchers at Sidney Kimmel Cancer Center have tested a strategy that combines radiotherapy with a drug that shuts down the ability of tumor to mend themselves.
Cancer treatment: Therapeutic approach gives hope for the treatment of multiple myeloma
A new therapeutic approach tested by a team from Maisonneuve-Rosemont Hospital (CIUSSS-EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy and for which the average life expectancy is about 6 or 7 years.
A new class of drug slows growth of castration-resistant prostate cancer cells
A first-in-class sphingosine kinase 2 inhibitor slowed the growth of castration-resistant prostate cancer cells, in part by inhibiting the enzyme dihydroceramide desaturase (DEGS), but did not kill them, according to the results of preclinical in vitro and in vivo studies published in the December 2015 issue of Molecular Cancer Therapeutics by researchers at the Medical University of South Carolina (MUSC) and others.
Three studies point to effectiveness of new therapies for multiple myeloma
In a trio of studies to be presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, investigators at Dana-Farber Cancer Institute will present the results of clinical trials showing that new drug combinations can significantly extend the time in which multiple myeloma is kept in check in patients with relapsed or treatment-resistant forms of the disease.
New vaccine strategy better protects high-risk cancer patients from flu
Yale Cancer Center researchers have developed a vaccine strategy that reduces the risk of flu infections in cancer patients at highest risk for influenza. The findings were presented Dec. 6 at the 57th annual meeting of the American Society of Hematology in Orlando, Florida.
Targeting protein homeostasis holds potential to treat solid tumors and blood cancers
The success of proteasome inhibitors such as VELCADEÂ® (bortezomib) and KyprolisÂ® (carfilzomib) for the treatment of multiple myeloma has shown that protein homeostasis, which is how cells maintain a balance of protein synthesis and degradation, is a valid pathway for developing drugs to treat cancer.
Personalized drug screening on horizon for multiple myeloma patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
More Multiple Myeloma Current Events and Multiple Myeloma News Articles